angiotensin-(1-7)   Click here for help

GtoPdb Ligand ID: 582

Synonyms: ang 1-7 | angiotensin 1-7 | TXA-127 | TXA127
Compound class: Endogenous peptide in human, mouse or rat
Comment: Angiotensin (1-7) is a naturally occurring peptide that is cleaved from angiotensin 1 or angiotensin 2 by the actions of the enzymes ACE2 and MME respectively.
Species: Human, Mouse, Rat
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

angiotensin-(1-7) is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CCC(C(C(=O)NC(C(=O)N1CCCC1C(=O)O)Cc1[nH]cnc1)NC(=O)C(NC(=O)C(C(C)C)NC(=O)C(NC(=O)C(CC(=O)O)N)CCCN=C(N)N)Cc1ccc(cc1)O)C
Isomeric SMILES CC[C@@H]([C@@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)O)Cc1[nH]cnc1)NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)N)CCCN=C(N)N)Cc1ccc(cc1)O)C
InChI InChI=1S/C41H62N12O11/c1-5-22(4)33(38(61)50-29(17-24-19-45-20-47-24)39(62)53-15-7-9-30(53)40(63)64)52-36(59)28(16-23-10-12-25(54)13-11-23)49-37(60)32(21(2)3)51-35(58)27(8-6-14-46-41(43)44)48-34(57)26(42)18-31(55)56/h10-13,19-22,26-30,32-33,54H,5-9,14-18,42H2,1-4H3,(H,45,47)(H,48,57)(H,49,60)(H,50,61)(H,51,58)(H,52,59)(H,55,56)(H,63,64)(H4,43,44,46)/t22-,26-,27-,28-,29-,30-,32-,33-/m0/s1
InChI Key PVHLMTREZMEJCG-GDTLVBQBSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
A pharmaceutical formulation of angiotensin (1-7) known as a TXA127 was advanced as a therapeutic by Tarix Pharmaceuticals for the management of rare neuromuscular and connective tissue diseases. Click here to link to ClinicalTrials.gov's full list of TXA127 trials. In June 2017 the EMA granted TXA127 orphan drug designation for the treatment of epidermolysis bullosa.

SARS-CoV-2 and COVID-19: In response to the COVID-19 pandemic, trials of angiotensin (1-7) in patients with severe COVID-19 were initiated, to determine if administration of angiotensin (1-7) might prevent acute kidney injury and deterioration into multi-organ failure in these patients. The proposition is that exogenous angiotensin (1-7) would normalise the angiotensin II/ angiotensin (1-7) balance that is disrupted by SARS-CoV-2 binding to ACE2 (loss of ACE2 > elevated/excessive angiotensin II > tissue injury).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04332666 Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial Phase 2/Phase 3 Interventional Erasme University Hospital
NCT04401423 TXA127 for the Treatment of Severe COVID-19 Phase 2 Interventional Columbia University